Publications by authors named "P Usai-Satta"
Article Synopsis
- Individuals with celiac disease (CD) may continue to experience gastrointestinal symptoms even while following a gluten-free diet (GFD), potentially due to the intake of fermentable carbohydrates known as FODMAPs.
- Research suggests that a low-FODMAP diet (LFD) could alleviate these symptoms and improve overall well-being for those with CD and non-celiac gluten sensitivity (NCGS).
- While the GFD remains the primary treatment for CD, evidence indicates that restricting FODMAPs can be beneficial for patients struggling with persistent symptoms.
Impact of a Symbiotic Mixture on Moderate-to-severe Diverticular Disease of the Colon.
Rev Recent Clin Trials
July 2024
Background: Microbial imbalance is thought to play a role in the pathogenesis of Diverticular Disease (DD).
Objective: We aimed to assess the efficacy of a symbiotic mixture (Prolactis GG Plus®) in the treatment of moderate to severe DD, scored according to the Diverticular Inflammation and Complication Assessment (DICA) classification.
Methods: A retrospective study was conducted enrolling the following patients: at the first diagnosis of DD; in whom DD was diagnosed with colonoscopy and scored according to DICA classification; treated with Prolactis GG Plus® two times/daily for 2 consecutive months; in whom the severity of the abdominal pain was scored with a 10-points visual-analogue scale (VAS) at baseline and the end of follow-up; in whom fecal calprotectin (FC) was assessed at baseline and the end of follow-up as μg/g.
The management of patients with diverticular disease remains challenging. The aim of this national survey was to assess how gastroenterologists and general practitioners use rifaximin to manage diverticulosis and diverticular disease. Members of the Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO) and the Italian Federation of General Practitioners (FIMMG) were invited to complete a 39-item online survey concerning the use of rifaximin in five clinical settings: (1) diverticulosis; (2) reducing symptoms in symptomatic uncomplicated diverticular disease; (3) reducing the occurrence of diverticulitis in patients with symptomatic uncomplicated diverticular disease (primary prevention); (4) reducing the recurrence of diverticulitis in patients with previous attacks of diverticulitis (secondary prevention); (5) treatment of uncomplicated acute diverticulitis.
View Article and Find Full Text PDFInflammatory bowel diseases, comprising Crohn's disease (CD) and ulcerative colitis (UC), are chronic, relapsing, and remitting immune-mediated inflammatory diseases affecting the gastrointestinal tract. Ustekinumab (UST) is a monoclonal antibody that blocks the p40 subunit of the anti-interleukin (IL) 12/23. Pivotal trials (CERTIFI and UNITI-IM for CD, UNIFI for UC) established the efficacy of UST for the induction and maintenance of remission in both CD and UC, with the most favorable results in naïve patients to biologics.
View Article and Find Full Text PDFBackground: Ustekinumab (UST) is an interleukin-12/interleukin-23 receptor antagonist recently approved for treating ulcerative colitis (UC) but with limited real-world data. Therefore, we evaluated the effectiveness and safety of UST in patients with UC in a real-world setting.
Research Design And Methods: This is a multicenter, retrospective, observational cohort study.